Acquisition synergies Certara Evidence & Access has integrated Analytica Laser and BaseCase, expanding end-to-end analytics and value communication capabilities. This creates cross-sell opportunities to clients seeking comprehensive value assessment, population health intelligence, and cloud-based value messaging.

Global delivery With 850+ employees across 14 US offices and 20 international locations, there is a broad geographic footprint ideal for selling as-a-service analytics, local market adaptation, and multinational pharmaceutical engagements across US, Europe, and Asia-Pacific.

AI and tech leverage Recent launches of agentic AI workflows and native Python API integration position Certara to offer advanced modeling, automation, and integration capabilities, appealing to R&D, regulatory, and medical writing teams seeking efficiencies and deeper insights.

Financial signal Recent quarter net loss due to higher costs and missing favorable adjustments suggests potential for customers to justify value-based partnerships and for Certara to emphasize ROI and total cost of ownership in proposals.

Industry validation Active participation in industry events such as PMx Approach Group 2026 and DMDG-GMP-SPS showcases, presenting case studies and new workflows, offering sales moments to demonstrate thought leadership and win new logos in biopharma, CRO, and regulated markets.